Pharmacokinetics, Safety and Tolerability After Multiple Dose Administration of BI 1467335 in Subjects With Moderate Renal Impairment and Subjects With Normal Renal Function (a Mono-centric, Open-label Study in Matched-group Design)
Phase of Trial: Phase I
Latest Information Update: 27 Aug 2018
At a glance
- Drugs BI 1467335 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis; Diabetic retinopathy; Non-alcoholic steatohepatitis; Renal fibrosis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 20 Aug 2018 Status changed from active, no longer recruiting to completed.
- 11 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Jul 2018 Planned End Date changed from 3 Aug 2018 to 20 Aug 2018.